Flynpovi (eflornithine;sulindac)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- eflornithine;sulindac
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Status
- Application withdrawn
- Therapeutic area
- Adenomatous Polyposis Coli
- Designations
- Orphan
- Application
- EMEA/H/C/005043
- ATC
- L01
- Official record
- www.ema.europa.eu
Indication
Treatment of adults patients with familial adenomatous polyposis (FAP)
Regulatory milestones
No milestones recorded in the last year.
Follow Flynpovi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.